In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Sight Sciences (SGHT – Research Report), with a price target of $5.50. The company’s shares closed last Friday at $3.05.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 3.0% and a 48.09% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Boston Scientific, and Staar Surgical.
Sight Sciences has an analyst consensus of Hold, with a price target consensus of $5.40, representing a 77.05% upside. In a report released on September 13, Morgan Stanley also maintained a Hold rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $15.30 and a one-year low of $2.78. Currently, Sight Sciences has an average volume of 196.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences (SGHT) Company Description:
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences price target lowered to $5 from $11 at Stifel
- Buy/Sell: Wall Street’s top 10 stock calls this week
- CVS upgraded, RTX downgraded: Wall Street’s top analyst calls
- Sight Sciences (NASDAQ:SGHT) Tanks 31% After Slashing Outlook
- Sight Sciences downgraded to Underperform at BofA on Medicare uncertainty
